In general, nembtabrutinib shows promising efficacy in the treatment of high-risk CLL patients with clinical resistance/relapse to previous therapy and successfully targets BTK-C481 mutations facilitating CLL cell resistance to several covalent BTK inhibitors. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.